Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immunology Expert, as Executive Vice President and Head of Research and Development, and Strengthens Scientific Advisory Board with the Addition of Dr. Adrian Ray
April 23, 2024 08:00 ET
|
Recludix Pharma, Inc.
Newly appointed head of R&D, Dr. Nirula, joins Recludix from Eli Lilly with over two decades of clinical development experience SAB member, Dr. Ray, has over two decades of experience in...
Recludix Pharma to Participate in Two Investor Conferences in March
February 28, 2024 08:00 ET
|
Recludix Pharma, Inc.
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that...
Recludix Pharma to Present at Two Investor Conferences in February
February 06, 2024 08:00 ET
|
Recludix Pharma, Inc.
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that...
Recludix Pharma to Present at Two Investor Conferences in November
November 09, 2023 08:00 ET
|
Recludix Pharma, Inc.
SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that...
Recludix Pharma Presents Preclinical Data Demonstrating Strong Efficacy and Favorable Safety Profile of REX-7117 Versus TYK2 and JAK Inhibitors at the Dermatology Drug Development Summit
October 31, 2023 16:00 ET
|
Recludix Pharma, Inc.
- REX-7117 found to have superior efficacy to a clinically-relevant dose of deucravacitinib in a preclinical model of psoriasis - REX-7117, as a highly selective STAT3 inhibitor, demonstrates...
Recludix Pharma Presents Preclinical Data from its STAT3 Inhibitor Program at the International Conference of the Inflammation Research Association (IRA)
October 17, 2023 16:00 ET
|
Recludix Pharma, Inc.
- Pioneering compounds believed to be the first orally administered reversible inhibitors to bind to and inhibit the SH2 domain potently and selectively - Proprietary STAT3 inhibitors are...
Recludix Pharma to Participate in Multiple Investor Conferences in September
August 30, 2023 08:00 ET
|
Recludix Pharma, Inc.
SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that...
Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications
July 20, 2023 08:00 ET
|
Recludix Pharma, Inc.
- Recludix to receive $125 million in near-term payments and potentially more than $1.2 billion subject to future milestones, and up to double-digit royalties on sales - - Recludix to lead research...
Recludix Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 07, 2023 08:00 ET
|
Recludix Pharma, Inc.
SAN DIEGO, March 07, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced that...
Recludix Pharma to Present at the Guggenheim Healthcare Talks Oncology Conference
February 01, 2023 08:00 ET
|
Recludix Pharma, Inc.
SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced that...